Latest Videos

Dr. Sagar Lonial discusses data from ASCO and EHA 2019 in transplant-eligible patients providing his thoughts on the key takeaways from the CASSIOPEIA trial. 

Dr. Xavier Leleu discusses new data from ASCO and EHA 2019 in patients with myeloma who are not transplant eligible. He also provides his thoughts on whether daratumumab might replace bortezomib.

Dr. Sagar Lonial discusses new data from ASCO and EHA 2019 in Relapsed-Refractory Myeloma

Dr. Xavier Leleu discusses data from ASCO and EHA 2019 on new agents in myeloma.

Dr. Xavier Leleu discusses Melflufen, a lipophilic peptide-conjugated alkylator

Dr. Richardson, MD discusses EHA 2018 Abstract S847: OPTIMISMM: Phase 3 Trial of POM, BORT, and Low‐Dose Dexamethasone vs BORT and Low-Dose Dexamethasone in Lenalidomide-Exposed Patients with RRMM

Dr. Iskander discusses EHA 2018 Abstract S849: Once-Weekly Vs Twice-Weekly Carfilzomib Dosing Plus Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Results of the Randomized Phase 3 Study A.R.R.O.W.

Dr. Francesca Gay discusses EHA 2018 Abstract PF560: Carfilzomib in Combination with Bendamustine and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Multicenter Phase Ib/II Trial of the EMNTG

Minimal Residual Disease (MRD) in Multiple Myeloma
Key Themes in Multiple Myeloma from ASH 2017

Dr. Xavier Leleu discusses data from ASCO and EHA 2019 in transplant-eligible patients, highlighting the key findings from the CASSIOPEIA trial.

Dr. Sagar Lonial discusses new data presented at ASCO and EHA 2019 in Smoldering Myeloma including an update on the IMWG Risk Stratification model and the ECOG randomized trial of lenalidomide vs. observation both of which have important implications in the treatment of patients.

Dr. Xavier Leleu discusses new data from ASCO and EHA 2019 in refractory myeloma.

Dr. Sagar Lonial discusses new data presented as ASCO and EHA 2019 on Cellular Therapies.

Dr. Gay discusses EHA 2018 Abstract S109: Updated Efficacy and MRD Data According to Risk-Status in Newly Diagnosed Myeloma Patients Treated with Carfilzomib Plus Lenalidomide or Cyclophosphamide: Results from the FORTE Trial

Dr. Bringhen discusses EHA 2018 abstract PS1293: Doublet vs Triplet LEN-Containing Regimens Followed by Maintenance: Subgroup Analysis by Frailty Status After a Median Follow-Up of 5 Years (EMN01 Phase III Study)

Dr. Dinmohamed from the IKNL discusses Abstract PS1301: Treatment and Survival of Patients with Primary Plasma Cell Leukemia: A Nationwide Population-Based Study Among 179 Patients Diagnosed in the Netherlands from 1989 to 2015

MOA and Its Impact on the Treatment of Multiple Myeloma
The Importance of MRD Testing in Multiple Myeloma

Additional Videos